Literature DB >> 20373258

Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling.

Andrea L Kasinski1, Frank J Slack.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to complementary sequences in mRNAs encoding downstream target genes. A large variety of cellular processes, including differentiation, development, apoptosis and cell cycle progression, are dependent on miRNA-mediated suppression of gene expression for their regulation. As such, it is unsurprising that these small RNA molecules are associated with signaling networks that are often altered in various diseases, including cancer. This review focuses on the function of miRNAs in three of the most well-documented signaling pathways that are dysregulated in tumors: the NFkappaB and Ras prosurvival signaling cascades and the tumor suppressor p53 pathway. Recent findings that connect these pathways through various miRNA families are reviewed, and support for using miRNA therapy as a novel method to counteract these tumor-promoting signaling events are presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373258

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  21 in total

Review 1.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

Review 2.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

Review 3.  Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy.

Authors:  Aamir Ahmad; Bernhard Biersack; Yiwei Li; Dejuan Kong; Bin Bao; Rainer Schobert; Subhash B Padhye; Fazlul H Sarkar
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

4.  Transcription factor NF-κB regulates expression of pore-forming Ca2+ channel unit, Orai1, and its activator, STIM1, to control Ca2+ entry and affect cellular functions.

Authors:  Anja Eylenstein; Sebastian Schmidt; Shuchen Gu; Wenting Yang; Evi Schmid; Eva-Maria Schmidt; Ioana Alesutan; Kalina Szteyn; Ivonne Regel; Ekaterina Shumilina; Florian Lang
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

Review 5.  Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2011-11-24       Impact factor: 60.716

6.  Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation.

Authors:  Risaku Fukumoto; Juliann G Kiang
Journal:  Radiat Res       Date:  2011-06-10       Impact factor: 2.841

Review 7.  The emerging role of microRNAs in drug responses.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Opin Mol Ther       Date:  2010-12

8.  MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation.

Authors:  Chaoqun Huang; Xiao Xiao; Ye Yang; Amorite Mishra; Yurong Liang; Xiangming Zeng; Xiaoyun Yang; Dao Xu; Michael R Blackburn; Craig A Henke; Lin Liu
Journal:  J Biol Chem       Date:  2017-07-18       Impact factor: 5.157

Review 9.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

Review 10.  MicroRNAs in the ionizing radiation response and in radiotherapy.

Authors:  Chanatip Metheetrairut; Frank J Slack
Journal:  Curr Opin Genet Dev       Date:  2013-02-28       Impact factor: 5.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.